Company intelligence / Profile preview

Signet Institute

Boston, Massachusetts, USAsignet.edu.au ↗

Ownership: Private
Development stage: Other

Overview

Signet Therapeutics is a clinical-stage biotech company pioneering first-in-class targeted therapies for difficult-to-treat cancers using organoid and AI-powered platforms. Its lead candidate, SIGX1094—a dual FAK/SRC inhibitor—has entered Phase 1 trials in diffuse gastric cancer after receiving both FDA Fast Track and Orphan Drug Designation. Preclinical data suggest broader potential in ovarian, triple-negative breast, pancreatic cancers, and as part of combination regimens with chemotherapy or other targeted agents.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

XtalPi (AI drug R&D collaboration)

Beyond the preview

Go deeper on Signet Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signet Institute.

Explore the full profile